Cargando…

Correction: Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102569/ http://dx.doi.org/10.1371/journal.pone.0103395

Ejemplares similares

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
por: Terme, Mickaël, et al.
Publicado: (2014)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
por: Mueller, Ina, et al.
Publicado: (2017)

Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells
por: Fisher, Jonathan P H, et al.
Publicado: (2015)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)
por: Arendt, A.-M., et al.
Publicado: (2023)

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
por: Simon, Thorsten, et al.
Publicado: (2011)

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside
por: Fleurence, Julien, et al.
Publicado: (2016)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
por: Bishop, Michael W., et al.
Publicado: (2020)

IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS
por: Abdel-Khaleq, Sameerah, et al.
Publicado: (2021)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
por: Schmitt, Julia, et al.
Publicado: (2022)

A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity
por: Alvarez-Rueda, Nidia, et al.
Publicado: (2011)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2020)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
por: Tivnan, Amanda, et al.
Publicado: (2017)

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
por: Ozkaynak, M. Fevzi, et al.
Publicado: (2018)

Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO
por: Diccianni, Mitchell B., et al.
Publicado: (2020)

Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation
por: Peng, Ching-An, et al.
Publicado: (2011)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
por: Evers, Mitchell, et al.
Publicado: (2021)

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy
por: McNerney, KO, et al.
Publicado: (2022)

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
por: Ozkaynak, M. Fevzi, et al.
Publicado: (2018)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy
por: Marachelian, Araz, et al.
Publicado: (2016)

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
por: Goldberg, Jacob L, et al.
Publicado: (2020)

Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986)

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells
por: Ly, Stanley, et al.
Publicado: (2021)

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients
por: Yu, Lihua, et al.
Publicado: (2021)

GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells
por: Durbas, Małgorzata, et al.
Publicado: (2018)

Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies
por: Sun, Xiaofei, et al.
Publicado: (2021)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Correction: Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
Publicado: (2020)

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
por: Fleurence, Julien, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ldl7hndakngrtfppt36bo1tnil